• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Bright Green Corporation filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    12/27/24 5:29:35 PM ET
    $BGXX
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BGXX alert in real time by email
    false 0001886799 0001886799 2024-12-20 2024-12-20 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

     

    FORM 8-K

     

    CURRENT REPORT

    PURSUANT TO SECTION 13 OR 15(d) OF

    THE SECURITIES EXCHANGE ACT OF 1934

     

    Date of Report (Date of earliest event reported): December 20, 2024

     

    Bright Green Corporation

    (Exact name of registrant as specified in its charter)

     

    Delaware   001-41395   83-4600841
    (State or other jurisdiction
    of incorporation)
      (Commission
    File Number)
      (I.R.S. Employer
    Identification No.)

     

    1033 George Hanosh Boulevard

    Grants, NM

      87020
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code: (833) 658-1799

     

     

     

    (Former name or former address, if changed since last report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading symbol(s)   Name of each exchange on which registered
    Common Stock, par value $0.0001 per share   BGXX   Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    SECTION 5 – CORPORATE GOVERNANCE AND MANAGEMENT

     

    Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

     

    On December 20, 2024, Mr. Gurvinder Singh resigned as a member of the board of directors (the “Board”) and as Chief Executive Officer of Bright Green Corp. (the “Company”). On same date, Sean Deson, Robert Arnone and Dean Valore resigned as members of the Board of the Company and Mr. Saleem Elmasri resigned as the Chief Financial Officer of the Company. Their resignations were not the result of a disagreement with the Company, known to an executive officer of the Company, on any matter relating to the Company’s operations, policies or practices.

     

    As a result of the above resignations of the Board, the sole member of the Board is the current Chair of the Company, Ms. Lynn Stockwell.

     

    On December 27, 2024, the Board appointed Ms. Lynn Stockwell as Chief Executive Officer. The employment history for Ms. Stockwell and material transactions she is involved in with our company are set forth in the Annual Report on Form 10-K/A filed with the SEC on April 29, 2024, and the Current Reports on Form 8-K filed with the SEC on August 19, 2024 and September 18, 2024.

     

    Section 7 - Regulation FD

     

    Item 7.01 Regulation FD Disclosure.

     

    On December 27, 2024, the Company issued a press release concerning the resignations, the new appointment as CEO, and a plan of restructuring.

     

    The press release is furnished with this Current Report on Form 8-K as Exhibits 99.1. The information furnished under this Item 7.01 and Item 9.01 of this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any registration statement or other filing under the Securities Act of 1933, as amended, regardless of any general incorporation by reference language in such filing, except as shall be expressly set forth by specific reference in any such filing.

     

    SECTION 9 – Financial Statements and Exhibits

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit No.   Description
    99.1   Press Release, dated December 27, 2024
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     2 
     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Bright Green Corporation  
       
    /s/ Lynn Stockwell  
    Lynn Stockwell  
    CEO and Director  
       
    Date December 27, 2024  

     

     3 

     

    Get the next $BGXX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $BGXX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BGXX
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Bright Green Corporation

      25-NSE - Bright Green Corp (0001886799) (Subject)

      3/21/25 11:19:49 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      3/21/25 9:15:14 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Financial Statements and Exhibits

      8-K - Bright Green Corp (0001886799) (Filer)

      2/27/25 4:05:24 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Bright Green Corporation Announces the next steps for the completion of its restructuring plan

      FORT LAUDERDALE, FLORIDA, March 21, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on March 17, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement, Disclosure Statement and Plan. The highlights of the Plan and Disclosure will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. Lynn Stockwell, the new Chief Executive Officer and Chairman of the Board of Directors of Bright Green Corporation, is also the

      3/21/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Announces the completion of its restructuring plan, withdraws from the Cannabis business and sets course on the production of all DEA Scheduled Controlled Substances

      FORT LAUDERDALE, FLORIDA, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on February 24, 2025, on behalf of the Company, Lynn Stockwell has asked the court to approve the "RSA" Restructuring Security Agreement. The highlights of the RSA will provide new equity for the company to pay all creditors with approved claims in full, in addition the Company equity shareholders will retain their interests in the Company and are unimpaired with no dilution. The Company in its restructuring efforts has entered into an agreement with the DEA to immediately withdraw all Cannabis related renewal applications. This agreement will a

      2/24/25 9:15:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Corporation Has Signed Agreement with Majority Shareholder as Plan Sponsor on Prepackaged Plan to Restructure the Company.

      The Company plans to emerge with federal loan guarantees for its 60 new mega farm owner/operators, that collectively will invest $3.5 billion to supply and strengthen the Drugs Made in America supply Chain. FORT LAUDERDALE, FLORIDA, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Bright Green Corporation (OTC:BGXX) ("Bright Green" or the "Company") announced that on January 21, 2025, it has entered into a Restructuring Support Agreement (the "RSA") with Lynn Stockwell, a major shareholder of the Company (the "Plan Sponsor") to restructure the Company. To implement the terms of the RSA, the Company will file, and the Plan Sponsor will support the Company's Prepackaged Plan of Reorganization Under Chapte

      1/27/25 8:17:00 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Leadership Updates

    Live Leadership Updates

    See more
    • (Updated) U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Jan. 14, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      1/14/24 10:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • U.S. Legal Cannabis Pioneer Bright Green Corporation Appoints Industry Veteran Groovy Singh as New Chief Executive Officer

      Singh's appointment comes in support of the Company's next evolution, which will be focused on investing in top talent, commencement of commercial operations, and investing in clinical research and development of plant based therapies, and expanding into cultivation and manufacturing of other scheduled substances. GRANTS, N.M., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Bright Green Corporation (NASDAQ:BGXX) ("Bright Green" or "the Company"), announced today their appointment of Groovy Singh, a renowned leader and strategist in the cannabis and wellness industries, as Chief Executive Officer. Singh will replace current CEO Seamus McAuley, who is stepping back from the position to address recently

      10/3/23 11:11:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bright Green Announces First Quarter 2023 Financial Update and Milestone Progress

      Bright Green has achieved several key milestones throughout the Quarter significantly advancing progress against its strategic plan, including a historic DEA Federal Registration and License Approval. Commencement of its fundamental capital raise of $500+ million utilizing the U.S. Citizen & Immigration Services EB-5 program, alongside the recently announced full acquisition of Alterola Biotech, showcases the Company's significant progress against its strategic plan. Company has raised short-term working Capital of $5.26m to commence its operations as it looks to capitalize on its historic DEA Registration in Q2 2023 and beyond. GRANTS, N.M., May 24, 2023 (GLOBE NEWSWIRE) -- Brig

      5/24/23 8:00:00 AM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D/A filed by Bright Green Corporation (Amendment)

      SC 13D/A - Bright Green Corp (0001886799) (Subject)

      9/6/23 5:19:19 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Bright Green Corporation

      SC 13D - Bright Green Corp (0001886799) (Subject)

      6/15/23 4:30:21 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G/A filed by Bright Green Corporation (Amendment)

      SC 13G/A - Bright Green Corp (0001886799) (Subject)

      6/12/23 5:28:12 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care

    $BGXX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Elmasri Saleem sold $4,951 worth of shares (25,942 units at $0.19), decreasing direct ownership by 2% to 1,103,476 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/11/24 4:05:11 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Elmasri Saleem sold $14,313 worth of shares (71,809 units at $0.20), decreasing direct ownership by 6% to 1,129,418 units (SEC Form 4)

      4 - Bright Green Corp (0001886799) (Issuer)

      9/10/24 4:05:08 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care
    • Amendment: Chief Executive Officer Singh Gurvinder was granted 5,500,000 shares (SEC Form 4)

      4/A - Bright Green Corp (0001886799) (Issuer)

      9/9/24 4:05:32 PM ET
      $BGXX
      Medicinal Chemicals and Botanical Products
      Health Care